Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
  • WIIM
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Earnings
  • News

Cellectar Biosciences FY EPS $(4.05) Misses $(3.91) Estimate; Cash & Cash Equivalents Of $19.9M Sufficient To Fund Operations Into Q4 2023

By Benzinga Newsdesk
Today, 7:25 AM
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(4.05) per share which missed the analyst consensus estimate of $(3.91) by 3.58 percent. This is a 6.9 percent increase over losses of $(4.35) per share

CLRB

Read More
2 minute read
  • Biotech
  • Events
  • FDA
  • General
  • News

Cellectar Biosciences Announces Presentation Of Data On CLR 12120 Series Of Targeted Alpha-Emitting Therapies At The 13th Annual World ADC Conference

By Benzinga Newsdesk
Today, 7:25 AM
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the

CLRB

Read More
1 minute read
  • News

Cellectar Biosciences Granted U.S. Patent #11,439,709 Phospholipid Ether Analogs as Cancer-targeting Drug Vehicles

By Charles Gross
Today, 7:25 AM
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6652&f=G&l=50&d=PTXT&p=134&S1=20220913&OS=20220913&RS=20220913

CLRB

Read More
1 minute read
  • Earnings

Cellectar Biosciences: Q2 Earnings Insights

By Benzinga Insights
Today, 7:25 AM
Cellectar Biosciences (NASDAQ:CLRB) reported its Q2 earnings results on Friday, August 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

CLRB

Read More
4 minute read
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

Why Energy Stocks Traded Higher; Here Are 61 Biggest Movers From Yesterday

By Lisa Levin
Today, 7:25 AM
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) jumped 150.4% to close at $1.59 on Monday after declining 8% on Friday.

ABOS

Read More
3 minute read
  • Intraday Update
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Why Is Infrastructure and Energy Alternatives Higher By Around 29%? 37 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin
Today, 7:25 AM
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 104% to $1.3263 after the company announced that primary endpoint was met in study for its treatment of allergic rhinitis.

ADXN

Read More
2 minute read
  • Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights
Today, 7:25 AM
Gainers Hanger (NYSE:HNGR) stock moved upwards by 27.1% to $18.75 during Thursday's after-market session. The company's market cap stands at $731.7 million.

BPTS

Read More
5 minute read
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday

By Lisa Levin
Today, 7:25 AM
Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednesday. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022.

ACTD

Read More
2 minute read
  • Intraday Update
  • Markets
  • Movers

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights
Today, 7:25 AM
 

ADIL

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Oppenheimer Assumes Cellectar Biosciences at Outperform, Announces Price Target of $5.5

By Benzinga Newsdesk
Today, 7:25 AM
Oppenheimer analyst Jeff Jones assumes Cellectar Biosciences (NASDAQ:CLRB) with a Outperform rating and announces Price Target of $5.5.

CLRB

Posts navigation

1 2 … 5 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service